Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 29, Issue 5, 2007, Pages 560-565

  Slish, Judianne ^a   Ma, Qing ^a   Zingman, Barry S ^b   Reichman, Richard C ^e   Fischl, Margaret A ^c   Gripshover, Barbara ^d   Forrest, Alan ^a   Brazeau, Dan ^a   Boston, Naomi S ^a   Catanzaro, Linda ^a   DiFrancesco, Robin ^a   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Antiretrovirals; Atazanavir; Lopinavir; TDM

Indexed keywords

AMPHETAMINE; ANABOLIC AGENT; ATAZANAVIR; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CANNABIS; COCAINE; LOPINAVIR; OPIATE; PHENCYCLIDINE; RITONAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDEPENDENT VARIABLE; MALE; PRIORITY JOURNAL; SUBSTANCE ABUSE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 34848824099     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31806db8ae     Document Type: Article

References (27)

1. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642-654.
2. HIV/AIDS, in Volkow N (ed): National Institute on Drug Abuse Research Report Series, 2006, p 1-8.
3. Francis H. Substance abuse and HIV infection. Topics in HIV Medicine. 2003;11:20-24.
4. Royce RA SA, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med. 1997;336:1072-1078.
5. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13:1099-1107.
6. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381.
7. Arici C, Ripamonti D, Maggiolo F, et al. Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials. 2002;3:52-57.
8. Woody GE, Gallop R, Luborsky L, et al. HIV risk reduction in the National Institute on Drug Abuse Cocaine Collaborative Treatment Study. J Acquir Immune Defic Syndr. 2003;33:82-87.
9. Lee W, Dieterich D. Challenges in the management of HIV and hepatitis C virus co-infection. Drugs. 2004;64:693-700.
10. Levin J. Hepatitis C Virus (HCV) and HCV/HIV Co-infection Handbook: Version V: National AIDS Treatment Advocacy Project; 2005. http://www.natap.org. Accessed April 24, 2007.
11. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005;40:174-181.
12. Mohsen AH, Easterbrook P, Taylor CB, et al. Hepatitis C and HIV-1 coinfection. Gut. 2002;51:601-608.
13. Giordano TP, Kramer JR, Souchek J, et al. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med. 2004;164:2349-2354.
14. Kramer JR, Giordano TP, Souchek J, et al. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005;42:309-314.
15. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779-789.
16. Telfer P, Sabin C, Devereux H, et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol. 1994;87:555-561.
17. Keil K FV, DiFrancesco R, Morse G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit. 2003;25:340-346.
18. Holland DT DR CJ, Morse GD. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit. 2006;28:367-374.
19. Holland DT DR SJ, Hamzeh F, Connor JD, Morse GD. Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824-831.
20. Acosta EP GJ. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002;18:825-834.
21. Micheli V, Meraviglia P, Regazzi M, et al. Lopinavir/r administration in HIV/HCV co-infected patients: pharmacokinetic considerations. Paper presented at the Second Annual European HIV Drug Resistance Workshop; March 2004; Rome, Italy.
22. Canta F, Marrone R, Bonora S, et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother. 2005;55:280-281.
23. Domínguez S. The HEPADOSE Study: differences of protease inhibitors and non-nucleoside analogue plasma concentrations between HIV/HCV and HIV patients [Abstract CI34]. Presented at the First International Workshop on HIV and Hepatitis Co-infection; December 2004; Amsterdam, The Netherlands.
24. Peng JZ, Pulido F, Causemaker SJ, et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol. 2006;46:265-274.
25. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423. Epub 2001; Sep 5.
26. Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544-546.
27. Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 2001;16:625-633.